Alkemata Morning Press Review — 27 October 2026

Quick take: Today’s consequential changes sit between promise and proof: a cancer drug improved survival but added toxicity; a hospital cyber failure interrupted care; EU platform rules gained an auditable plan; and Spain softened its proposed test for data-centre electricity.

A targeted drug extends survival in advanced endometrial cancer

Merck reported on 26 October that its antibody–drug conjugate sacituzumab tirumotecan, or sac-TMT, reduced the risk of death by 32% against physicians’ choice of chemotherapy in a randomized Phase 3 trial of 776 people whose advanced or recurrent endometrial cancer had progressed after platinum chemotherapy and immunotherapy. Median survival was 19 months, compared with 12.1 months; the US Food and Drug Administration has accepted a priority review, with a target decision on 15 June 2027. The result is promising because the drug targets TROP2, a protein common on these tumours, to deliver a cell-killing payload more selectively. It is not yet approved, and the company-reported evidence carries a serious trade-off: grade 3 or worse treatment-related adverse events affected 54.4% of patients, versus 41.4% with chemotherapy. For patients, this is a possible future option, not a reason to change treatment unaided. Ask an oncology team whether the trial population resembles your case, what supportive care the side effects require, and whether an appropriate clinical trial is open. Sources: Merck, 26 October 2026; Reuters, 26 October 2026.

Possible Alkemata article: When a Longer Cancer Survival Comes with Heavier Toxicity

A hospital cyber failure becomes a patient-access crisis

On 26 October, the University of New Mexico Health System diverted ambulances, told people not to attend its main hospital and cancelled appointments across more than 30 clinics while responding to a cybersecurity issue. That temporarily left New Mexico without an emergency department able to treat the most serious trauma. Operations began returning in phases later that day, but the system and investigators had not established the incident’s nature or scope; claims displayed on staff computers about stolen data were not independently confirmed. The encouraging part was mutual aid: two other health systems accepted additional patients. The danger is the concentration revealed by the disruption—one digital failure removed the state’s only Level 1 trauma centre from normal service. For an individual, cyber resilience can determine whether care is physically reachable, not merely whether records remain private. Keep a current medication and allergy list offline, know an alternative urgent-care or emergency location, and follow the health system’s official status page rather than messages circulating on social media. Source: Associated Press, 26 October 2026.

Possible Alkemata article: When Hospital Cybersecurity Becomes Clinical Continuity

Temu’s EU safety plan moves from promise to a four-month test

The European Commission accepted Temu’s action plan on 26 October following the €200 million Digital Services Act fine imposed in May for deficient assessment of illegal-product risks. The five-part plan requires platform-specific, current evidence; reliable measures of whether mitigations work; examination of the limits of proactive moderation; and analysis of how recommendations or deliberate manipulation may amplify illegal listings. Temu has four months to complete an interim risk assessment covering the six months to 30 November and must subject its measures to an external independent audit. That is promising because it turns “safety” into evidence regulators can inspect. Acceptance, however, is not proof that unsafe goods have disappeared, and other EU concerns about addictive design, recommendation transparency and researcher access remain open. Shoppers are directly concerned when chargers, toys or small appliances evade product rules. Before buying a safety-critical item, identify the responsible EU trader, check official recall databases and retain the listing and seller details; a low price or platform badge is not conformity evidence. Sources: European Commission, 26 October 2026; Reuters, 26 October 2026.

Possible Alkemata article: Can a Marketplace Prove Its Product-Safety System Works?

Spain’s data-centre proposal becomes narrower and slower

This is materially new since the 26 August review: Spain’s revised draft decree would now apply its principal conditions only to data centres above 10 megawatts, rather than above one megawatt, and would let qualifying projects take up to five years to reach the requirement that renewable power cover at least 80% of supply in every operating hour. The 26 October proposal also expands the look-back period for matching new demand with newly installed renewable capacity from 18 to 36 months, with no time limit for solar. The flexibility may prevent viable projects being rejected because construction and grid schedules do not align. The danger is equally concrete: excluding smaller facilities and delaying hourly matching could shift more fossil-powered demand and grid costs onto the public during the transition. This remains a proposal, not a completed rule. Residents and local authorities should request hourly load, additional renewable capacity, water use and backup-generation data for each project—and ask whether multiple sub-10-megawatt sites could avoid the threshold. Source: Reuters, 26 October 2026.

Possible Alkemata article: What Hourly Renewable Matching Reveals About Data Centres